Of vasectomies, vitamins and prostate-cancer risk: Hutchinson Center study examines the links

October 20, 1999

For men concerned about prostate-cancer risk, here's some good news from researchers at the Fred Hutchinson Cancer Research Center in Seattle: The above findings, reported in a pair of papers that will appear Friday in Cancer Epidemiology, Biomarkers and Prevention, stem from the largest study ever designed to look at prostate-cancer risk and vasectomy in men under age 65. The results of this $1.8 million National Cancer Institute-funded study should allay any residual misgivings about a potential link between cancer risk and vasectomy, says lead researcher Dr. Janet Stanford, head of the Hutchinson Center's Prostate Cancer Research Program.

"We looked carefully at this large population with a high prevalence of vasectomy and didn't see an association with prostate cancer," says Stanford, a member of the Center's Public Health Sciences Division and a research professor of epidemiology at UW. "This is an important public-health question, and we believe that our results will be reassuring to physicians performing the procedure and to couples selecting vasectomy for contraception," she says. Vasectomy costs less than tubal ligation, the surgical-contraceptive counterpart for women, and is associated with fewer side effects.

While several other recent studies also have found no association between vasectomy and prostate cancer, the National Cancer Institute commissioned the Hutchinson Center study to address lingering doubt stemming from earlier studies that had suggested a link. Researchers from the University of Washington School of Public Health and Community Medicine and Seattle's Northwest Prostate Institute also collaborated on the study.

While some of the earlier studies were flawed substantially by factors ranging from selection bias to second-hand data collection, other investigations of more rigorous scientific design reported conflicting results that raised legitimate concern about a possible association between vasectomy and prostate cancer, Stanford says.

The Hutchinson Center's five-year study of 1,456 men ages 40 to 64 compared 753 men in King County who had prostate cancer to 703 who did not. In addition to whether they'd had a vasectomy, the men answered questions regarding medical history, screening for prostate cancer, and a number of lifestyle choices, including diet and the use of vitamin and mineral supplements. The research team adjusted for variables such as age, race and family history of prostate cancer. The results showed that the prevalence of vasectomy within the two groups was similar: 39.4 percent of those with prostate cancer had undergone vasectomy compared to 37.7 percent of the non-cancer group. After adjustment for confounding factors, there was no association found between vasectomy and risk of prostate cancer.

The researchers also questioned the men about the frequency and duration of dietary-supplement use, specifically regarding four types of multivitamins (with and without minerals) and six individual nutritional supplements: vitamins A, C and E, and calcium, iron and zinc.

Analysis of the supplement data indicates that fewer than one-third of the men in both groups took daily multivitamins, while 21 percent took vitamin C and 14 percent took vitamin E. Only 5 percent took daily doses of zinc, calcium or vitamin A.

Men who took daily doses of vitamins C or vitamin E had a 23 percent lower risk of prostate cancer, while those who took zinc daily decreased their risk by 45 percent.

While these results are suggestive, men should not change their use of dietary supplements based on this study alone, cautions Dr. Alan Kristal, who led the analysis of the supplement data and was the lead author on the vitamin-supplement paper.

"There are so few studies of dietary supplements and prostate-cancer risk that even with these results we still don't know enough about it to make any recommendations," says Kristal, a member of the Cancer Prevention Research Program in the Center's Public Health Sciences Division and a UW professor of epidemiology.

The results for the zinc supplements, which were unexpected, are consistent with earlier clinical studies that find much lower concentrations of zinc in cancerous prostate tissue compared to healthy prostate tissue. Zinc may play some role in regulating healthy prostate growth. The results for vitamin E on cancer risk were somewhat smaller than the protective effect found in one previous study.

Overall, Kristal says, the study adds weight to the idea that some supplemental vitamins and minerals may influence prostate-cancer risk.

The researchers suggest that further studies on dietary supplements and prostate-cancer risk should include a large population-based survey that incorporates blood-sample collection to better examine exposures to differing combinations and doses of supplements.
Media contact: Kristen Woodward, Fred Hutchinson Cancer Research Center, (206) 667-5095.

Fred Hutchinson Cancer Research Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.